ELAN INVESTMENT UPDATE: BFA Law Notifies Elanco Investors Who Lost Money to Contact Firm About Securities Class Fraud Investigation

Why did Elanco’s share price fall?

Elanco develops products to treat diseases in animals. Two of the leading treatments in the company’s development pipeline are currently under review by the U.S. Food and Drug Administration (“FDA”). The treatments are Zenrelia, a drug for a type of dermatitis in dogs, and Credelio Quattro, a broad-spectrum oral parasiticide that treats fleas, ticks and internal parasites.

Regarding these treatments, the company stated that the FDA “has all the data necessary to complete the review. All technical sections, including the label, are expected to be approved before the end of June (2024).” However, on June 27, 2024, Elanco announced that it did not expect the FDA to approve either drug in June 2024 and that Zenrelia would come with a boxed safety warning.

As a result of the news, Elanco’s stock price fell more than 21%, from $17.97 per share on June 26, 2024 to $14.27 per share on June 27, 2024. BFA Law is investigating whether Elanco and certain executives made materially false and/or misleading statements to investors regarding the FDA approval of its drugs.

Click here if you have suffered a loss: https://www.bfalaw.com/cases-investigations/elanco-animal-health-incor….

What can you do?

If you have invested in Elanco Animal Health Incorporated (NYSE: ELAN), you may have legal options and are encouraged to provide your information to the company. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any legal fees or costs. The company will seek court approval for any costs and expenses.

You can submit your details via:

https://www.bfalaw.com/cases-investigations/elanco-animal-health-incor…

Why Bleichmar Fonti & Auld LLP?

Bleichmar Fonti & Auld LLP is a leading global law firm representing plaintiffs in securities class action lawsuits and shareholder lawsuits. It was named one of the Top 5 Plaintiffs’ Law Firms for 2023 by ISS SCAS and its attorneys have been named Titans of the Plaintiffs’ Bar by Law360 and Thompson Reuters. Among its recent notable successes, BFA has recovered over $900 million in equity from the board of directors of Tesla, Inc. (pending court approval), as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, visit https://www.bfalaw.com.

https://www.bfalaw.com/cases-investigations/elanco-animal-health-incor…

Advertisement of lawyer. Past results are no guarantee of future results.

To view the source version of this press release, visit https://www.newsfilecorp.com/release/220257

The Elanco Animal Health Stock had fallen by 1.5% at the time of the news release. -1.66 % to 12.92EUR on the Tradegate exchange (August 19, 2024, 09:30 AM).